These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11342323)

  • 1. Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab.
    O'Dwyer ME; Launder T; Rabkin JM; Nichols CR
    Leuk Lymphoma; 2000 Oct; 39(3-4):411-9. PubMed ID: 11342323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Post-transplantation lymphoproliferative disorder in childhood].
    Stréhn A; Szőnyi L; Kriván G; Kovács L; Reusz G; Szabó A; Rényi I; Kovács G; Dezsőfi A
    Orv Hetil; 2014 Feb; 155(8):313-8. PubMed ID: 24534879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab.
    Maldonado NI; Cabanillas F; Jaffe ES; Raffeld M; Lozada L
    J Clin Oncol; 2011 Aug; 29(22):e658-60. PubMed ID: 21646613
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
    Zilz ND; Olson LJ; McGregor CG
    J Heart Lung Transplant; 2001 Jul; 20(7):770-2. PubMed ID: 11448808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplant lymphoproliferative disorder presenting as multiple myeloma.
    Ninan MJ; Datta YH
    Am J Hematol; 2010 Aug; 85(8):635-7. PubMed ID: 20578201
    [No Abstract]   [Full Text] [Related]  

  • 8. Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab.
    Muzaffar M; Taj A; Ratnam S
    Am J Ther; 2010; 17(6):e230-3. PubMed ID: 19918163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
    Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
    Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review.
    Zhu K; Chen J; Chen S
    Hematology; 2005 Oct; 10(5):365-70. PubMed ID: 16273722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus-associated post-transplant lymphoproliferative disorder of plasma cell type following allogeneic haemopoietic stem cell transplant treated with rituximab.
    Getta B; Kwan J
    Intern Med J; 2014 Aug; 44(8):821. PubMed ID: 25081050
    [No Abstract]   [Full Text] [Related]  

  • 13. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system.
    van de Glind G; de Graaf S; Klein C; Cornelissen M; Maecker B; Loeffen J
    Pediatr Blood Cancer; 2008 Apr; 50(4):886-8. PubMed ID: 17668865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EBV-positive B cell cerebral lymphoma 12 years after sex-mismatched kidney transplantation: post-transplant lymphoproliferative disorder or donor-derived lymphoma?
    Phelan PJ; Murphy RK; Farrell M; O'Toole O; Heffernan J; O'Brien D; Breathnach O; Conlon PJ
    Nephrol Dial Transplant; 2010 Jun; 25(6):2032-5. PubMed ID: 20348150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder.
    Hirokawa M; Kawabata Y; Fujishima N; Yoshioka T; Sawada K
    Int J Hematol; 2007 Oct; 86(3):291-2. PubMed ID: 17989001
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation.
    Herman J; Vandenberghe P; van den Heuvel I; Van Cleemput J; Winnepenninckx V; Van Damme-Lombaerts R
    J Heart Lung Transplant; 2002 Dec; 21(12):1304-9. PubMed ID: 12490276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab.
    Ifthikharuddin JJ; Mieles LA; Rosenblatt JD; Ryan CK; Sahasrabudhe DM
    Am J Hematol; 2000 Oct; 65(2):171-3. PubMed ID: 10996837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low viral load post-transplant lymphoproliferative disease localized within the tongue.
    Henry DD; Hunger SP; Braylan RC; Dharnidharka VR
    Transpl Infect Dis; 2008 Dec; 10(6):426-30. PubMed ID: 18657087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
    Garcia VD; Bonamigo Filho JL; Neumann J; Fogliatto L; Geiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Ferrera des Santos A; Roithmann S
    Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.